Skip to main content
Log in

PS2 - 3. The effect of INGAP, FGF7 and a GLP-1R agonist on the differentiation of primary human duct cells towards beta cells

  • Published:
Nederlands Tijdschrift voor Diabetologie Aims and scope

Abstract

Beta cell replacement by islet transplantation is a promising treatment for patients with type 1 diabetes mellitus. However, shortage of donor tissue demands for an alternative source to generate beta cells. Cells from the pancreatic duct compartment are an attractive alternative source for beta cell replacement therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeetindra R.A. Balak.

Additional information

1 Department of Nephrology, LUMC, Albinusdreef 2, Leiden, The Netherlands, 2 Hubrecht Institute, Uppsalalaan 8, Utrecht, The Netherlands. E-mail: J.R.A.Balak@lumc.nl

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balak, J., Spijker, H., Loomans, C. et al. PS2 - 3. The effect of INGAP, FGF7 and a GLP-1R agonist on the differentiation of primary human duct cells towards beta cells. NED. TIJDSCHR. DIABET. 11, 137–138 (2013). https://doi.org/10.1007/s12467-013-0071-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12467-013-0071-1

Keywords

Navigation